Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized magnesium sulfate added to salbutamol and hypertonic saline for infant bronchiolitis
IRCT20201122049461N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of magnesium sulfate, salbutamol and hypertonic saline in bronchiolitis (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Oxygen saturation, Body temperature and 3 more. Started Sep 2022; status: completed.
02
Drugs
magnesium sulfatesalbutamolhypertonic saline
03
Conditions
bronchiolitis
Beyond the preview
Go deeper on IRCT20201122049461N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201122049461N1.